Since our goal is to enhance patient involvement across all facets of cancer clinical research conducted by EORTC, our newest initiative is to appoint a patient representative as a member of the Independent Data Monitoring Committee
IDMC is an independent body aiming to evaluate the accumulating data during the course of clinical trials, assure that the risk-benefit ratio is maintained, and make recommendations on modifications or even early termination of the study. Since the duty of this committee is to ensure the safety of patients and scientific integrity of the trials, we believe it would be invaluable to have patient representatives on board.
Patients’ perspectives can help us understand whether:
- scientific value of the trial is sufficient,
- participation in the trial is feasible for patients, and whether the investigated therapy
brings important (positive or negative) changes for patients.